HalfLifeDBEvidence before certainty.

1P-LSD evidence profile

The cited biotransformation work supports describing 1P-LSD as an LSD prodrug, but it does not establish a representative human elimination half-life for 1P-LSD itself.

Category: psychedelic · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References2Linked studies, labels, reviews, or identity records described below

1P-LSD: evidence and interpretation notes

Why HalfLifeDB does not plot 1P-LSD

The cited biotransformation work supports describing 1P-LSD as an LSD prodrug, but it does not establish a representative human elimination half-life for 1P-LSD itself. An LSD-derived proxy would answer a different question, so this profile publishes the evidence gap instead of a curve.

What each source contributes

  • PubChem: 1P-LSD. This identity record confirms names and compound identity and does not supply a human half-life.
  • Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). This metabolism study identifies pathways, metabolites, or analytical targets and does not by itself create a complete human concentration-time curve.

For 1P-LSD, the decision to withhold a curve turns on the limits visible in Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). This metabolism study identifies pathways, metabolites, or analytical targets, but it does not by itself create a complete human concentration-time curve.

What evidence would change the page

For 1P-LSD, stronger evidence means more than detection or biological activity: it means a clearly reported human elimination estimate tied to one analyte and route. That numerical bridge is absent from Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

InterpretationCategory context and evidence limits

psychedelic context

Psychedelic duration is shaped by pharmacodynamics as well as pharmacokinetics, so subjective effects may not track a simple elimination curve.

  • The curve does not predict psychological effects or functional safety.
  • Metabolites and downstream receptor activity are not separately modeled.
  • Published estimates may come from small or specialized study populations.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC0 DailyMed1 PubChem
  1. Identity record PubChem Compound Summary: 1P-LSD.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
  2. Research abstract PubMed: Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
    Metabolism-focused evidence used to identify pathways or analytes. It does not automatically establish a population half-life.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.